CD19 and lymphoma: In their study, the authors pointed out that CD19 is a major B Cell Receptor (BCR)-independent regulator of c-MYC levels in B cell neoplasms by activating the PI3K/AKT/GSK3 axis to promote B cell transformation and lymphoma progression [49,50].